278789-43-8

Basic information

• Product Name: N-Boc-3-Methylnipecotic acid ethyl ester
• Synonyms: 1-(tert-Butoxycarbonyl)-3-(ethoxycarbonyl)-3-methylpiperidine;3-Methyl-1,3-piperidinedicarboxylic acid 1-(1,1-dimethylethyl) 3-ethyl ester;Ethyl 1-(tert-butoxycarbonyl)-3-methylpiperidine-3-carboxylate;N-Boc-3-Methylnipecotic acid ethyl ester;1,3-Piperidinedicarboxylic acid, 3-methyl-, 1-(1,1-dimethylethyl) 3-ethyl ester;3-methyl-1,3-piperidinedicarboxylic acid 1-(1,1-;dimethylethyl) 3-ethyl ester;1-tert-butyl 3-ethyl 3-methylpiperidine-1,3-dicarboxylate
• CAS NO: 278789-43-8
• Molecular Formula: C₁₄H₂₅NO₄
• Molecular Weight: 271.35
• Mol File: 278789-43-8.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 329.7 °C at 760 mmHg
• Flash Point: 153.2 °C
• Appearance: /
• Density: 1.054
• Vapor Pressure: 0.000175mmHg at 25°C
• Refractive Index: 1.468
• Storage Temp.: 2-8°C
• PKA: -2.37±0.40(Predicted)
• CAS DataBase Reference: N-Boc-3-Methylnipecotic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: N-Boc-3-Methylnipecotic acid ethyl ester(278789-43-8)
• EPA Substance Registry System: N-Boc-3-Methylnipecotic acid ethyl ester(278789-43-8)

Safety Data

• Hazardous Substances Data: 278789-43-8(Hazardous Substances Data)

Usage

General Description

N-Boc-3-Methylnipecotic acid ethyl ester is a chemical compound that belongs to the class of esters. It is derived from nipecotic acid, which is a GABA reuptake inhibitor that may have potential therapeutic applications in the treatment of anxiety or epilepsy. The N-Boc-3-Methylnipecotic acid ethyl ester compound is often used in medicinal chemistry research to synthesize new potential drug candidates or to study the structure-activity relationships of GABAergic compounds. It is also used as a building block in organic synthesis and can be modified to create different derivatives with varied pharmacological properties. Overall, N-Boc-3-Methylnipecotic acid ethyl ester is an important compound in the field of medicinal chemistry and drug discovery.

InChI:InChI=1/C14H25NO4/c1-6-18-11(16)14(5)8-7-9-15(10-14)12(17)19-13(2,3)4/h6-10H2,1-5H3

Upstream product

• 191599-51-6 ethyl (S)-1-[(tert-butoxy)carbonyl]piperidine-3-carboxylate 
• 74-88-4 methyl iodide 
• 148672-74-6 ethyl N-(t-butyloxycarbonyl)nipecotate 
• 71962-74-8 Ethyl nipecotate 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 406212-48-4 tert-butyl 3-(hydroxymethyl)-3-methylpiperidine-1-carboxylate 
• 1094074-07-3 C₁₆H₂₃NO₃ 
• 1094074-06-2 C₁₆H₂₃NO₃ 
• 1094071-28-9 C₁₆H₂₃NO₃ 
• 176523-95-8 ethyl 3-methylpiperidine-3-carboxylate hydrochloride 
• 492450-80-3 1-(5-chloro-2-methyl-phenylthiocarbamoyl)-3-methyl-piperidine-3-carboxylic acid ethyl ester 
• 170843-43-3 3-methylpiperidine-3-carboxylic acid ethyl ester 

Relevant articles and documents

PHARMACOLOGICALLY ACTIVE ALICYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES

The present invention relates to new pyrazolo[l,5-a]pyrimidine derivatives of formula (I) or pharmaceutical ly acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof that serve as GABAB receptor positive allosteric modulators. The invention al so relates to the process for producing such compounds. The invention further relates to pharmaceutical compositions comprising such compounds optionally in combination with two or more different therapeutic agents and the use of such compounds in methods for treating diseases and conditions mediated and modulated by the GABAB receptor positive allosteric mechanism. The invention al so provides a method for manufacture of medicaments useful in the treatment of such disorders.

JAK INHIBITOR

The present invention discloses a series of JAK inhibitors, and particularly discloses a compound of formula (I) or a pharmaceutically acceptable salt thereof and the use thereof in preparation of drugs for treating diseases related to JAK.

2-ACYLAMINOTHIAZOLE DERIVATIVE AND SALT THEREOF

[Problem] A compound which is useful as an active ingredient of a pharmaceutical composition for treating storage dysfunctions, voiding dysfunctions, and lower urinary tract diseases is provided. [Means for Solution] The present inventors have found that a thiazole derivative having pyrazine-2-carbonylamino substituted at the 2-position is an excellent muscarinic M 3 receptor positive allosteric modulator, and is useful as an agent for preventing and/or treating bladder or urinary tract diseases, related to bladder contraction by a muscarinic M 3 receptor, thereby completing the present invention. The 2-acylaminothiazole derivative or a salt thereof of the present invention can be used as an agent for preventing and/or treating bladder or urinary tract diseases, related to bladder contraction by a muscarinic M 3 receptor, for example, voiding dysfunctions such as underactive bladder.